404 related articles for article (PubMed ID: 23148799)
1. An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan.
Landy SH; Tepper SJ; Wein T; Schweizer E; Ramos E
Headache; 2013 Jan; 53(1):118-125. PubMed ID: 23148799
[TBL] [Abstract][Full Text] [Related]
2. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
[TBL] [Abstract][Full Text] [Related]
3. An open study of self-administration of subcutaneous sumatriptan to treat successive attacks of acute migraine. Portuguese Sumatriptan Auto-injector Study Group.
J Int Med Res; 1994; 22(4):225-35. PubMed ID: 7958382
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study.
Landy S; Munjal S; Brand-Schieber E; Rapoport AM
J Headache Pain; 2018 Aug; 19(1):70. PubMed ID: 30112725
[TBL] [Abstract][Full Text] [Related]
5. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group.
Eur Neurol; 1991; 31(5):323-31. PubMed ID: 1653140
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of subcutaneous sumatriptan using a novel self-injector.
Gross ML; Kay J; Turner AM; Jewsbury J; Cleal AL
Headache; 1995; 35(10):601-6. PubMed ID: 8550361
[TBL] [Abstract][Full Text] [Related]
7. Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice.
Jensen K; Tfelt-Hansen P; Hansen EW; Krøis EH; Pedersen OS
Cephalalgia; 1995 Oct; 15(5):423-9. PubMed ID: 8536304
[TBL] [Abstract][Full Text] [Related]
8. Comparison of subcutaneous sumatriptan with usual acute treatments for migraine. French Sumatriptan Study Group.
Boureau F; Chazot G; Emile J; Bertin L; d'Allens H
Eur Neurol; 1995; 35(5):264-9. PubMed ID: 8542914
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
[TBL] [Abstract][Full Text] [Related]
10. Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans.
Cady RK; Aurora SK; Brandes JL; Rothrock JF; Myers JA; Fox AW; Farr SJ
Headache; 2011 Sep; 51(8):1202-11. PubMed ID: 21812775
[TBL] [Abstract][Full Text] [Related]
11. Sumatriptan in acute migraine using a novel cartridge system self-injector. United Kingdom Study Group.
Gross ML; Kay J; Turner AM; Hallett K; Cleal AL; Hassani H
Headache; 1994; 34(10):559-63. PubMed ID: 7843948
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.
Munjal S; Brand-Schieber E; Allenby K; Spierings ELH; Cady RK; Rapoport AM
J Headache Pain; 2017 Dec; 18(1):31. PubMed ID: 28251391
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults.
Wendt J; Cady R; Singer R; Peters K; Webster C; Kori S; Byrd S
Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463
[TBL] [Abstract][Full Text] [Related]
14. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine.
Diamond S; Elkind A; Jackson RT; Ryan R; DeBussey S; Asgharnejad M
Arch Fam Med; 1998; 7(3):234-40. PubMed ID: 9596457
[TBL] [Abstract][Full Text] [Related]
15. Sumatriptan transdermal system can be correctly assembled and applied during migraine attacks.
Meadows KP; Pierce M; O'Neill C; Foster S; Jennings C
Headache; 2014 May; 54(5):850-60. PubMed ID: 24708392
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study.
Carpay J; Schoenen J; Ahmad F; Kinrade F; Boswell D
Clin Ther; 2004 Feb; 26(2):214-23. PubMed ID: 15038944
[TBL] [Abstract][Full Text] [Related]
17. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache.
Plosker GL; McTavish D
Drugs; 1994 Apr; 47(4):622-51. PubMed ID: 7516861
[TBL] [Abstract][Full Text] [Related]
18. Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescents.
McDonald SA; Hershey AD; Pearlman E; Lewis D; Winner PK; Rothner D; Linder SL; Runken MC; Richard NE; Derosier FJ
Headache; 2011 Oct; 51(9):1374-87. PubMed ID: 21797863
[TBL] [Abstract][Full Text] [Related]
19. Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study.
Fujita M; Sato K; Nishioka H; Sakai F
Cephalalgia; 2014 Apr; 34(5):365-75. PubMed ID: 24163282
[TBL] [Abstract][Full Text] [Related]
20. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group.
Göbel H; Winter P; Boswell D; Crisp A; Becker W; Hauge T; Mihout B; Niewold J; Tørring J
Clin Ther; 2000 Aug; 22(8):981-9. PubMed ID: 10972634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
